SGM
VRDN icon

Seven Grand Managers’s Viridian Therapeutics VRDN Stock Holding History

Seven Grand Managers’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$919K Buy
+50,000
New +$806K 0.04% 161
2026
Q1 		– Sell
-100,000
Closed -$3.11M – 192
2025
Q4 		$3.11M Buy
+100,000
New +$2.74M 0.24% 92
2022
Q4 		– Sell
-25,000
Closed -$513K – 21
2022
Q3 		$513K Buy
+25,000
New +$449K 1.68% 16

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Seven Grand Managers's VRDN Position: Q2 2026 in Review

Seven Grand Managers opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 50,000 shares worth $919K. The stake represents 0.04% of the portfolio and ranks #161 among its holdings. This is a return to the name: Seven Grand Managers previously reported a position in VRDN as recently as Q4 2025.

Seven Grand Managers first reported a position in VRDN in Q3 2022 and has held it in 3 quarters since. The position peaked at $3.11M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Seven Grand Managers held 50,000 shares of Viridian Therapeutics worth $919K as of Q2 2026.
  • Viridian Therapeutics was a new Seven Grand Managers position in Q2 2026.
  • Viridian Therapeutics made up 0.04% of Seven Grand Managers's portfolio in Q2 2026, its #161 holding.
  • Seven Grand Managers first reported a position in Viridian Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • Seven Grand Managers's Viridian Therapeutics position peaked at $3.11M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.